The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity.
Where this comes from
- Record sourced from PubMed, PMID 39297680.
- Also identified by DOI 10.1073/pnas.2415550121 and PMC identifier 11441540.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity. Each of the three had a distinct set of skills that made this advance possible; Habener is an endocrinologist and molecular biologist, Mojsov is a peptide chemist, and Knudsen is a pharmaceutical scientist. Their collective efforts have done what few thought possible-the development of highly effective medicines for reducing weight. Their research has also solved a mystery that began more than a century ago.
Medical subject headings
- Obesity
- Glucagon-Like Peptide 1